Prothena Corp. Plc (PRTA)

11.39
0.20 1.73
NASDAQ : Health Technology
Prev Close 11.59
Open 11.64
Day Low/High 11.15 / 11.92
52 Wk Low/High 8.63 / 46.14
Volume 195.89K
Avg Volume 429.60K
Exchange NASDAQ
Shares Outstanding 39.86M
Market Cap 477.17M
EPS -4.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Today's Dead Cat Bounce Stock Is Prothena (PRTA)

Today's Dead Cat Bounce Stock Is Prothena (PRTA)

Trade-Ideas LLC identified Prothena (PRTA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Weak On High Volume: Prothena (PRTA)

Weak On High Volume: Prothena (PRTA)

Trade-Ideas LLC identified Prothena (PRTA) as a weak on high relative volume candidate

Prothena (PRTA) Flagged As Strong On High Volume

Prothena (PRTA) Flagged As Strong On High Volume

Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate

Stock To Watch: Prothena (PRTA) In Perilous Reversal

Stock To Watch: Prothena (PRTA) In Perilous Reversal

Trade-Ideas LLC identified Prothena (PRTA) as a "perilous reversal" (up big yesterday but down big today) candidate

Prothena (PRTA) Strong On High Relative Volume Today

Prothena (PRTA) Strong On High Relative Volume Today

Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate

First Week Of May 20th Options Trading For Prothena (PRTA)

First Week Of May 20th Options Trading For Prothena (PRTA)

Investors in Prothena Corp plc saw new options become available this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PRTA options chain for the new May 20th contracts and identified one put and one call contract of particular interest.

Trade-Ideas: Prothena (PRTA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Prothena (PRTA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate

Data From Prothena's Preclinical Program On Conformation-Specific Antibodies Against Misfolded Transthyretin Published In Amyloid

Data From Prothena's Preclinical Program On Conformation-Specific Antibodies Against Misfolded Transthyretin Published In Amyloid

Antibodies bind specifically to misfolded, non-native forms of transthyretin, disrupting fibril formation

Prothena (PRTA) Marked As A Dead Cat Bounce Stock

Prothena (PRTA) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Prothena (PRTA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Interesting PRTA Put And Call Options For April 15th

Interesting PRTA Put And Call Options For April 15th

Investors in Prothena Corp plc saw new options become available this week, for the April 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PRTA options chain for the new April 15th contracts and identified one put and one call contract of particular interest.

Prothena (PRTA): Today's Weak On High Volume Stock

Prothena (PRTA): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Prothena (PRTA) as a weak on high relative volume candidate

Oversold Conditions For Prothena Corp

Oversold Conditions For Prothena Corp

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Data From Prothena's Ongoing Phase 1/2 Clinical Trial Of NEOD001 In AL Amyloidosis Published In The Journal Of Clinical Oncology

Data From Prothena's Ongoing Phase 1/2 Clinical Trial Of NEOD001 In AL Amyloidosis Published In The Journal Of Clinical Oncology

Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association

Commit To Buy Prothena Corp At $25, Earn 12.3% Annualized Using Options

Commit To Buy Prothena Corp At $25, Earn 12.3% Annualized Using Options

Investors considering a purchase of Prothena Corp plc stock, but tentative about paying the going market price of $41.02/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $25 strike, which has a bid at the time of this writing of $2.00.

Prothena (PRTA) Showing Signs Of A Dead Cat Bounce Today

Prothena (PRTA) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Prothena (PRTA) as a "dead cat bounce" (down big yesterday but up big today) candidate

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.

Despite Shkreli Drama, Retrophin Looks Interesting Now

Despite Shkreli Drama, Retrophin Looks Interesting Now

One biotech portfolio manager thinks Retrophin, the biotech company once run by indicted hedge fund manager Martin Shkreli, could be a promising investment.

TheStreet Quant Rating: D (Sell)